Arterra Bioscience S.p.A. (BIT:ARBS)
Italy · Delayed Price · Currency is EUR 3.080
0.00 (0.00%)
Jul 27, 2026, 3:43 PM CET
Arterra Bioscience Cash Flow Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 2.01 | 1.34 | 1.08 | 1.41 | 1.11 |
Depreciation & Amortization | 0.29 | 0.34 | 0.53 | 0.53 | 0.49 |
Other Adjustments | 0.19 | 0.6 | 0.25 | 0.53 | 0.13 |
Change in Receivables | -0.22 | 0.05 | -0.18 | 0.29 | -0.76 |
Changes in Inventories | -0.21 | 0.03 | -0.2 | -0.67 | 0.08 |
Changes in Accounts Payable | -0.04 | 0.03 | 0.06 | -0.06 | 0.06 |
Changes in Accrued Expenses | 0.14 | -0.15 | -0.09 | -0.25 | 0.12 |
Changes in Income Taxes Payable | -0.16 | -0.31 | -0.59 | -0.38 | -0.16 |
Changes in Other Operating Activities | -0.01 | -0.86 | 0.16 | -0.01 | 0.32 |
Operating Cash Flow | 1.99 | 1.06 | 1.03 | 1.4 | 1.4 |
Operating Cash Flow Growth | 87.22% | 3.73% | -26.48% | -0.11% | 191.10% |
Investing Activities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | -0.45 | -0.64 | -0.07 | -0.09 | -0.54 |
Sale of Property, Plant & Equipment | - | 0.05 | 0.02 | 0.04 | - |
Purchases of Intangible Assets | -0.02 | - | -0.02 | -0 | -0.07 |
Proceeds from Sale of Intangible Assets | 0 | - | - | - | - |
Purchases of Investments | -3.45 | -0.1 | -2.37 | -1.63 | -0.5 |
Proceeds from Sale of Investments | 0.85 | - | 1.6 | - | - |
Investing Cash Flow | -3.05 | -0.71 | -0.84 | -1.69 | -1.11 |
Financing Activities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Short-Term Debt Issued | 0 | 0.03 | 0.1 | -0.04 | 0 |
Net Short-Term Debt Issued (Repaid) | 0 | 0.03 | 0.1 | -0.04 | 0 |
Long-Term Debt Repaid | -0.1 | -0.06 | -0.2 | -0.08 | -0.2 |
Net Long-Term Debt Issued (Repaid) | -0.1 | -0.06 | -0.2 | -0.08 | -0.2 |
Issuance of Common Stock | - | - | -0.13 | - | 0.18 |
Net Common Stock Issued (Repurchased) | - | - | -0.13 | - | 0.18 |
Common Dividends Paid | -0.85 | -0.67 | -0.67 | - | - |
Financing Cash Flow | -0.94 | -0.7 | -0.89 | -0.13 | -0.01 |
Net Cash Flow
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Cash Flow | -2 | -0.34 | -0.71 | -0.42 | 0.28 |
Free Cash Flow
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 1.54 | 0.42 | 0.96 | 1.3 | 0.86 |
Free Cash Flow Growth | 263.33% | -55.88% | -26.22% | 51.99% | 521.51% |
FCF Margin | 25.17% | 8.04% | 19.39% | 24.53% | 18.57% |
Free Cash Flow Per Share | 0.23 | 0.06 | 0.14 | 0.20 | 0.13 |
Levered Free Cash Flow | 1.47 | -0.26 | 0.79 | 0.36 | 1.29 |
Unlevered Free Cash Flow | 1.5 | -0.49 | 0.69 | 0.33 | 1.46 |